LIVER: Edited by Don RockeyStem cell therapy in chronic liver diseaseTakami, Taroa; Terai, Shujib; Sakaida, IsaobAuthor Information aDivision of Laboratory, Yamaguchi University Hospital, Yamaguchi University School of Medicine bDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan Correspondence to Isao Sakaida, MD, PhD, Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Minami-kogushi 1-1-1, Ube, Yamaguchi 755-8505, Japan. Tel: +81 836 22 2238; fax: +81 836 22 2240; e-mail: [email protected] Current Opinion in Gastroenterology: May 2012 - Volume 28 - Issue 3 - p 203-208 doi: 10.1097/MOG.0b013e3283521d6a Buy Metrics Abstract Purpose of review To provide an overview of the current status of liver regeneration therapies for liver cirrhosis and future prospects. Recent findings Various clinical studies for liver disease have been reported, including hepatic administration of autologous CD34-positive cells induced by granulocyte colony-stimulating factor, portal vein administration of CD133-positive mononuclear cells, and administration of autologous bone marrow-derived mesenchymal stem cells. Effectiveness of these approaches has been shown in some patients. We have also reported improved liver fibrosis and function with infusion of autologous bone marrow cells in a basic study with mice, and on the basis of those results started autologous bone marrow cell infusion (ABMi) therapy for liver cirrhosis. The efficacy and safety of ABMi therapy has also been reported by other institutions. Summary Results of recent clinical studies strongly suggest that liver function-improving effects can be achieved using infusion of bone marrow (stem) cells for cirrhosis. New treatment methods using less-invasive bone marrow-derived cultured cells need to be developed. © 2012 Lippincott Williams & Wilkins, Inc.